Diligence memo · auto-generated · as of July 2, 2026
Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Intra-Cellular Therapies, Inc. operates in Biotechnology, based in NEW YORK.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Intra-Cellular Therapies, Inc. has raised $70M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $70M on 2013-08-29.
Most recent recorded round closed around 2013-08-29.
Valuation (modeled)modeled
Provath models Intra-Cellular Therapies, Inc. at approximately $2.9B (range $217M–$7.6B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.27× the median modeled value of Series C Biotechnology companies in 2013–2015 (41 peers) — value vs value, same stage and era. Within the normal band (127% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 12.8 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 86% of Biotechnology peers (4293 compared).
Modeled value ranks above 97% of those peers.
Closest niche peers: Antigenics LLC/DE, Naurex Inc., Fluidigm Corp, Tengion Inc, Spark Therapeutics, Inc..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.